DPYS Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- 产品详情
- 实验流程
- 背景知识
Application ![]()
| IHC-P, WB |
---|---|
Primary Accession | Q14117 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 56630 Da |
Isotype | Rabbit IgG |
Antigen Source | HUMAN |
Gene ID | 1807 |
---|---|
Antigen Region | 454-482 aa |
Other Names | Dihydropyrimidinase, DHP, DHPase, Dihydropyrimidine amidohydrolase, Hydantoinase, DPYS |
Dilution | IHC-P~~1:100~500 WB~~1:1000 |
Target/Specificity | This DPYS antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 454-482 amino acids from the C-terminal region of human DPYS. |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | DPYS Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | DPYS |
---|---|
Function | Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyze the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate. |
Tissue Location | Liver and kidney. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Dihydropyrimidinase catalyzes the conversion of 5,6-dihydrouracil to 3-ureidopropionate in pyrimidine metabolism. Dihydropyrimidinase is expressed at a high level in liver and kidney as a major 2.5-kb transcript and a minor 3.8-kb transcript. Defects in the DPYS gene are linked to dihydropyrimidinuria.
REFERENCES
Kim, H.Y., et al. BMB Rep 43(8):547-553(2010)
van Kuilenburg, A.B., et al. Biochim. Biophys. Acta 1802 (7-8), 639-648 (2010) :
Fidlerova, J., et al. Cancer Chemother. Pharmacol. 65(4):661-669(2010)
Thomas, H.R., et al. Pharmacogenet. Genomics 18(1):25-35(2008)
Thomas, H.R., et al. Pharmacogenet. Genomics 17(11):973-987(2007)

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.